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Edited by Peter Tontonoz and Laszlo NagyAbstract Adiponectin is an abundantly expressed adipokine in
adipose tissue and has direct insulin sensitizing activity. A
decrease in the circulating levels of adiponectin by interactions
between genetic factors and environmental factors causing obes-
ity has been shown to contribute to the development of insulin
resistance, type 2 diabetes, metabolic syndrome and atheroscle-
rosis. In addition to its insulin sensitizing actions, adiponectin
has central actions in the regulation of energy homeostasis.
Adiponectin enhances AMP-activated protein kinase activity in
the arcuate hypothalamus via its receptor AdipoR1 to stimulate
food intake and decreases energy expenditure. We propose a
hypothesis on the physiological role of adiponectin: a starvation
gene in the course of evolution by promoting fat storage on
facing the loss of adiposity.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Obesity-linked insulin resistance is a key feature of type 2
diabetes, metabolic syndrome and cardiovascular diseases
[32,29,11]. White adipose tissue (WAT) has been recognized
as an important endocrine organ that secretes a number of bio-
logically active adipokines [10,42,34,24]. Dysregulation of
these adipokines have been shown to aﬀect insulin sensitivity
through modulation of insulin signaling pathway such as phos-
phorylation of the insulin receptor substrate (IRS) proteins
(e.g. IRS1 and IRS2) [10] and the molecules involved in glu-
cose and lipid metabolism in the peripheral tissues such as liver
and skeletal muscle [33]. Of these adipokines, adiponectin has
recently attracted much attention because of its antidiabetic
and antiatherogenic eﬀects [39,3,4,8,12,30,13]. Indeed, a de-
crease in the circulating levels of adiponectin by interactions
between genetic factors and environmental factors causing
obesity has been shown to contribute to the development of*Corresponding author. Address: Department of Metabolic Diseases,
Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
E-mail address: kadowaki-3im@h.u-tokyo.ac.jp (T. Kadowaki).
0014-5793/$32.00  2007 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2007.11.070insulin resistance, type 2 diabetes, the metabolic syndrome
and atherosclerosis (Fig. 1) [12,13].
In addition to these peripheral actions, adipokines have also
been reported to have central actions in the regulation of en-
ergy homeostasis. Leptin binds is known to bind to the leptin
receptor (LRb) in the hypothalamus and activates JAK2 (Ja-
nus kinase 2)-STAT3 (signal transducer and activator of tran-
scription 3) and phosphatidylinositol-3 kinase (PI3K) pathway
to increase metabolic rate and sympathetic tone and suppress
feeding, thereby decreasing body weight [7]. Moreover, leptin
has been reported to inhibit AMP-activated protein kinase
(AMPK) activity in the hypothalamus and suppress food in-
take [28]. Recently, like leptin, adiponectin has been demon-
strated to play an important role in the central nervous
system (CNS). Adiponectin was shown to be present in the
CSF of rodents [31,22] and human [23,19,6] and to enter the
CSF from the circulation [31,22]. Moreover, the adiponectin
receptors adipoR1 and adipoR2 [40] were found to be ex-
pressed in the hypothalamus and brain endothelial cells
[35,22].
In this Review, we outline the recent progress in research on
the physiological and pathophysiological role of adiponectin
and adiponectin receptors in the peripheral tissues and CNS.
Since the length of this Review is limited, we recommend that
readers also consult other recent reviews on adiponectin re-
search [4,12,13,30].2. Cloning, function, and regulation of adiponectin receptors
In order to understand the molecular mechanism of adipo-
nectin action, we isolated cDNA for human adiponectin recep-
tors [40]. The cDNA encoded a protein designated adiponectin
receptor 1 (AdipoR1) [40]. This protein is structurally
conserved from yeast to humans (especially in the 7 transmem-
brane domains). Interestingly, the yeast homologue
(YOL002c) plays a key role in metabolic pathways that regu-
late lipid metabolism, such as fatty acid oxidation [14]. More-
over, we found a gene that was signiﬁcantly homologous (67%
amino acid identity) with AdipoR1, which was termed Adi-
poR2 [40]. AdipoR1 is ubiquitously expressed, including in
skeletal muscle and liver, whereas AdipoR2 is most abun-
dantly expressed in the liver. AdipoR1 and AdipoR2 appear
to be integral membrane proteins; the N-terminus is internal
and the C-terminus is external-opposite to the topology ofblished by Elsevier B.V. All rights reserved.
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Fig. 1. Decrease in the circulating levels of adiponectin by interactions between genetic factors and environmental factors causing obesity has been
shown to contribute to the development of insulin resistance, type 2 diabetes, the metabolic syndrome and atherosclerosis [12].
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Expression of AdipoR1 and AdipoR2 or suppression of Adi-
poR1 and AdipoR2 expression supports our conclusion that
AdipoR1 and AdipoR2 serve as receptors for globular and
full-length adiponectin and mediate increased AMPK, PPARa
and p38 MAP kinase activities as well as fatty-acid oxidation
and glucose uptake by adiponectin.
Recently, a two-hybrid study revealed that the C-terminal
extracellular domain of AdipoR1 interacted with adiponec-
tin, whereas the N-terminal cytoplasmic domain of Adi-
poR1 interacted with APPL (adaptor protein containing
pleckstrin homology domain, phosphotyrosine-binding do-
main, and leucine zipper motif) [26]. Moreover, interaction
of APPL with AdipoR1 in mammalian cells was stimulated
by adiponectin binding, and this interaction appeared to
play an important role in adiponectin-mediated AMPK acti-
vation and downstream eﬀects [26].The expression levels of
both AdipoR1 and AdipoR2 were signiﬁcantly decreased
in insulin-resistant ob/ob mice, probably in part because of
obesity-linked hyperinsulinaemia [36]. Moreover, adiponec-
tin-induced activation of AMPK was signiﬁcantly decreased,
for example, in the skeletal muscle of ob/ob mice, suggesting
that adiponectin resistance is present in ob/ob mice [36].
Thus, obesity decreases not only plasma adiponectin levels
but also AdipoR1/R2 expression, thereby causing adiponec-
tin resistance and leading to insulin resistance, which in
turn aggravates hyperinsulinaemia, forming a vicious cycle
[36].3. Expression of adiponectin receptors in the liver ameliorated
diabetes
Consistent with the data in ob/ob mice, expression levels of
AdipoR1 or AdipoR2 were decreased to approximately 65%
or 55%, respectively, in the liver of db/db mice as compared
with wild-type mice. To determine the role of decreased expres-
sion levels of AdipoRs in the development of the insulin resis-
tance and diabetes observed in obese mice, we studied the
eﬀects of adenovirus-mediated restoration of AdipoR1 expres-
sion in db/db mice. In fact, adenovirus-mediated overexpres-
sion of AdipoR1 or AdipoR2 in the liver of db/db mice
signiﬁcantly improved insulin resistance and diabetes in db/
db mice [41].3.1. AdipoR1 increases AMPK activation by adiponectin in liver
Expression of AdipoR1 resulted in signiﬁcantly increased
activation of AMPK in the liver by adiponectin, whereas
expression of AdipoR2 did not. Activation of AMPK in the
liver has been reported to reduce the expression of genes
encoding hepatic gluconeogenic enzymes such as glucose-6-
phosphatase (G6pc) and phosphoenolpyruvate carboxykinase
1 (Pck1) [25] as well as genes encoding molecules involved in
lipogenesis such as sterol regulatory element binding protein
1c (Srebf1) [37]. In fact, expression of AdipoR1 signiﬁcantly
decreased the expressions of G6pc, Pck1 and Srebf1 in the liver
of db/db mice, which may be among mechanisms by which res-
toration of AdipoR1 in the liver reduced endogenous glucose
production (EGP), apparently increased glucose infusion rate
(GIR) and improved diabetes [41]. In contrast, expression of
AdipoR2 had little eﬀects on the expression levels of G6pc,
Pck1 or Srebf1. These results suggested that AdipoR1 may
be more involved in the activation of AMPK by adiponectin
than AdipoR2 in liver in vivo [41].3.2. AdipoR2 increases PPARa target genes in liver
Expression of AdipoR2 signiﬁcantly increased the expres-
sion of genes encoding molecules involved in glucose uptake
such as glucokinase (Gck) [27], unlike the molecules involved
in gluconeogenesis, which appeared to be one possible mech-
anism by which AdipoR2 expression in the liver apparently
increased GIR and improved diabetes. On the other hand,
expression of AdipoR1 had little eﬀect on the expression lev-
els of Gck. Expression of AdipoR2 in liver of db/db mice in-
creased PPARa (Ppara) itself [41] and its target genes [16]
such as Acox1 (acyl-CoA oxidase) and Ucp2 (uncoupling
protein 2), whereas expression of AdipoR1 in liver of db/
db mice had little eﬀects on PPARa itself and its target
genes such as Acox1 and Ucp2. These observations suggested
that AdipoR2 may be more involved in activation of the
PPARa pathways than AdipoR1. Adenovirus-mediated
expression of AdipoR1 or AdipoR2 in the liver of db/db
mice signiﬁcantly increased fatty-acid oxidation, and tended
to decrease hepatic triglyceride content, which may be one
mechanism by which expression of AdipoR1 or AdipoR2
in the liver improved insulin resistance and diabetes [41]
(Fig. 2). The present data suggest that down-regulation of
AdipoR1 and AdipoR2 in obesity plays causal roles, at least
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Fig. 2. AdipoR1 appears to mediate its biological eﬀects via AMPK, whereas AdipoR2 appears to mediate them via PPARa.
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diabetes.4. AdipoR1 and AdipoR2 serve as the major adiponectin receptor
in vivo
We generated AdipoR1 knockout mice, AdipoR2 knockout
mice and AdipoR1/R2 double knockout mice [41]. AdipoR1
knockout mice showed signiﬁcantly impaired glucose tolerance
and insulin resistance. EGP was signiﬁcantly increased and
GIR was signiﬁcantly decreased in AdipoR1 knockout mice
as compared with the wild-type mice. These observations indi-
cate increased hepatic glucose production and insulin resis-
tance in liver of AdipoR1 knockout mice. Although glucose
intolerance was not observed in AdipoR2 knockout mice, plas-
ma insulin levels were found to be signiﬁcantly higher in the
AdipoR2 knockout mice than in the wild-type mice, suggesting
the presence of insulin resistance in the AdipoR2 knockout
mice. In contrast to AdipoR1 knockout mice, EGP was not sig-
niﬁcantly higher in AdipoR2 knockout mice. However, GIR
was signiﬁcantly decreased, and Rd tended to be decreased
in AdipoR2 knockout mice. AdipoR1/R2 double knockout
mice exhibited signiﬁcantly impaired glucose tolerance and
insulin resistance. There is a signiﬁcant elevation of the insulin
resistance index in the AdipoR1/R2 double knockout mice
compared to the AdipoR1 knockout mice, and this can be
attributed to the contribution of the AdipoR2 deﬁciency.
These ﬁndings provided the ﬁrst direct evidence that AdipoR1
and AdipoR2 do indeed play important physiological roles in
the regulation of insulin sensitivity in vivo. Liver is a major tar-
get of adiponectin action [3]. We detected no appreciable
adiponectin speciﬁc binding activity in the hepatocytes from
AdipoR1/R2 double knockout mice, indicating undetectable
levels of functional adiponectin receptors in hepatocytes from
AdipoR1/R2 double knockout mice. Consistent with this, glu-
cose lowering eﬀect of adiponectin was completely abrogated
in AdipoR1/R2 double knockout mice. Thus, AdipoR1 and
AdipoR2 are the major adiponectin receptors in vivo, which
mediate the major, if not the entire, part of adiponectin bind-
ing and adiponectin actions.5. Adiponectin receptors are present in the hypothalamus, and
adiponectin enters the CSF from the circulation
Since the end of the 19th century, several eﬀorts have been
made to determine the CNS role in the regulation of energy
metabolism. In 1953, Gordon Kennedy proposed a ‘‘lipostat
theory’’ that body fat content is maintained by factors secreted
from adipose tissue, as a result of feedback signals arising from
the fat depots that are sensed by the brain [15]. The hormone
leptin circulates in proportion to body fat [2]. Leptin informs
the CNS that adipose stores are expanding and prevents from
accumulating excessive fat storage through coordinated regu-
lation of feeding, metabolism, the autonomic nervous system
and body energy balance. In contrast, no adipokine has been
identiﬁed that promotes fat accumulation when energy balance
is disrupted.
AdipoR1 and AdipoR2 [40], were found to be abundantly
expressed in the hypothalamus, and their expression levels
were comparable to those in the liver. In situ hybridization
analysis revealed the expressions of AdipoR1 and AdipoR2
as well as the leptin receptor in the ARH. Immunohistochem-
ical analysis revealed colocalization of AdipoR1 and the leptin
receptor in the ARH of C57BL/6 mice. Adiponectin was de-
tected in the CSF of C57BL/6 mice at approximately 1/
4000th of its concentration in the serum; it was also detected
in the CSF of adiponectin knockout mice [20,21] after intrave-
nous (i.v.) injection of full-length adiponectin administered to
raise the serum adiponectin levels in these mice to approxi-
mately the same levels as in wild-type mice. These ﬁndings
indicate that adiponectin does indeed enter the CSF from the
circulation [22]. Adiponectin is known to exist in three forms,
namely, trimers, hexamers, and HMW multimers, in the serum
of wild-type mice. Interestingly, unlike in the serum, only tri-
mers and hexamers, and not HMW multimers, were found in
the CSF of the wild-type mice. In adiponectin knockout mice,
after i.v. injection of full-length adiponectin, all three forms,
i.e., trimers, hexamers, and HMW multimers, were found in
the serum, while only trimers and hexamers, and not HMW
multimers, were found in the CSF. These data indicate that
the distribution of the multimeric forms of adiponectin in the
CSF diﬀers from that in the serum [22]. In wild-type mice,
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leptin increased signiﬁcantly after refeeding, serum and CSF
adiponectin levels decreased signiﬁcantly. In addition, the
expression of AdipoR1 in the ARH decreased signiﬁcantly
after refeeding, whereas that of AdipoR2 remained unchanged.6. Adiponectin increases AMPK activity in the ARH via
AdipoR1 to stimulate food intake
In view of the increases in adiponectin concentrations in the
serum and CSF and the increases in the AdipoR1 expression
level in the ARH under fasting conditions, adiponectin signals
may be involved in the stimulation of food intake. It has been
suggested that adiponectin is an orexigenic hormone and that
it may stimulate the phosphorylation of AMPK and acetyl-
CoA carboxylase (ACC), downstream of AMPK, in the hypo-
thalamus [1,9,5,38]. Phosphorylation of AMPK and ACC was
suppressed after refeeding [1,28,38]. Administration of adipo-
nectin increased the phosphorylation of AMPK and ACC.
Next, we investigated whether the enhanced AMPK activation
by adiponectin was mediated by the adiponectin receptors ex-
pressed in the ARH by injecting adeno-AdipoR1 siRNA or
adeno-AdipoR2 siRNA into the ARH, using adeno-LacZ as
a control. The phosphorylation of AMPK and ACC in the
ARH was signiﬁcantly suppressed in the adeno-AdipoR1 siR-
NA-treated mice as compared with the adeno-LacZ-treated
mice under fasting conditions. After refeeding, phosphoryla-
tion of AMPK and ACC was also suppressed in the control
group treated with adeno-LacZ, and this was reversed by the
administration of adiponectin. However, in the animals in
which AdipoR1 expression in the ARH was decreased by
treatment with AdipoR1 siRNA, adiponectin failed to reverse
the suppression of AMPK and ACC phosphorylation ob-
served after refeeding. On the other hand, when AdipoR2
expression in the ARH was reduced by the administration of
AdipoR2 siRNA, the suppression of AMPK and ACC phos-
phorylation after refeeding was still reversed by adiponectin.
These ﬁndings suggest that adiponectin directly activates
AMPK in the ARH via AdipoR1, but not AdipoR2. Since in-
creased AMPK activity in the ARH has been shown to stimu-
late food intake [9,28,5], we then investigated the eﬀect of
adiponectin on food intake. Food intake after refeeding was
signiﬁcantly lower than after fasting, as the AMPK and
ACC phosphorylation levels decreased. Adiponectin injection
signiﬁcantly increased food intake after refeeding, as the
AMPK and ACC phosphorylation levels increased. In the
mice in which AdipoR1 expression in the ARH was decreased
by treatment with AdipoR1 siRNA, the stimulation of food in-
take by adiponectin injection was blunted. On the other hand,
in the mice in which AdipoR2 expression in the ARH was de-
creased by treatment with AdipoR2 siRNA, no such blunting
of the eﬀect of adiponectin injection was observed. These ﬁnd-
ings suggest that adiponectin stimulates food intake via Adi-
poR1 in the ARH. Next, in order to investigate whether the
stimulation of food intake induced by adiponectin is actually
mediated by AMPK, dominant-negative AMPK (D/N-
AMPK) was expressed in the ARH, and the amount of food
intake was measured. In the control group treated with LacZ,
the amount of food consumed after adiponectin injection was
signiﬁcantly higher than after saline injection. In contrast, in
the group treated with D/N-AMPK, the stimulation of foodintake by the adiponectin injection was blunted, suggesting
that adiponectin has a central action of stimulating food intake
by activating AMPK in the ARH. In addition to regulating
food intake, AMPK in the hypothalamus is also thought to
regulate energy expenditure [9,5,17]. Examination of the eﬀect
of adiponectin on energy expenditure revealed that oxygen
consumption was signiﬁcantly decreased by adiponectin. Con-
sistent with these ﬁndings, expression of uncoupling protein 1
(UCP1) in brown adipose tissue (BAT) was signiﬁcantly de-
creased after i.v. injection of adiponectin. We then adminis-
tered the hexameric form of adiponectin, the predominant
form in the CSF, directly into the lateral cerebral ventricles
and examined the direct eﬀects of adiponectin in order to rule
out the possibility that the actions of adiponectin on the
peripheral organs participate in the AMPK activation in the
ARH and stimulation of food intake. The suppression of
AMPK and ACC phosphorylation after refeeding was indeed
reversed by intracerebroventricular (i.c.v.) administration of
the hexameric form of adiponectin. Intracerebroventricular
injection of the hexameric form of adiponectin also signiﬁ-
cantly stimulated food intake after refeeding, along with
increasing the AMPK and ACC phosphorylation levels. More-
over, oxygen consumption was signiﬁcantly decreased follow-
ing i.c.v. injection of the hexameric form of adiponectin.
Intravenous injection of adiponectin decreased energy expen-
diture and UCP1 expression in BAT. Taken together, these
ﬁndings indicate that adiponectin directly regulates AMPK
activity in the ARH and food intake.
Scherers group has generated adiponectin-transgenic ob/ob
mice that show serum adiponectin levels 2–3-fold higher than
ob/ob mice [18]. These mice also show markedly increased
body weight due to decreased energy expenditure, as mani-
fested by lower body temperature and lower oxygen consump-
tion, consistent with our observations that adiponectin
decreases energy expenditure.7. Adiponectin knockout mice exhibit decreased AMPK activity
in the ARH, increased oxygen consumption, and greater loss
of fat during fasting
In order to further elucidate the physiological role of adipo-
nectin in the CNS, we investigated the eﬀects of adiponectin
deﬁciency on AMPK activity, food intake, and energy homeo-
stasis in adiponectin knockout mice. AMPK phosphorylation
in the ARH was signiﬁcantly suppressed in adiponectin knock-
out mice after fasting. Expression of neuropeptide Y (NPY) in
the ARH after fasting was also signiﬁcantly lower in adiponec-
tin knockout mice, while the expression of pro-opiomelanocor-
tin (POMC) in the ARH was increased after fasting in these
mice. Consistent with the decreased AMPK activity and de-
creased NPY expression in the ARH, adiponectin knockout
mice consumed signiﬁcantly more oxygen than their wild-type
littermates under fasting conditions. Expression of UCP1 in
BAT was signiﬁcantly increased in adiponectin knockout mice
as compared with wild-type mice. Moreover, despite the adipo-
nectin deﬁciency, AMPK phosphorylation in skeletal muscle
was signiﬁcantly increased in adiponectin knockout mice com-
pared to their wild-type littermates. These increases in UCP1
expression and AMPK phosphorylation, which may account
for the increased energy expenditure in adiponectin knockout
mice, cannot be explained by the peripheral actions of adipo-
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tions. Despite the similar body weight of wild-type and adipo-
nectin knockout mice, body fat mass, as measured by dual
energy X-ray absorptiometry (DEXA), was signiﬁcantly lower
in adiponectin knockout mice than in wild-type mice. The
reduction in visceral and subcutaneous fat mass after fasting
was greater in adiponectin knockout mice than in wild-type
mice.Leptin Adiponectin
Hypo-
thalamus8. Adiponectin knockout mice exhibit reduced food intake and
increased oxygen consumption and appear to be protected
from high-fat diet-induced obesity
Adiponectin knockout mice were found to be more resistant
to high-fat diet (HFD)-induced obesity than wild-type mice.
The visceral WAT mass and subcutaneous WAT mass were
both signiﬁcantly smaller in adiponectin knockout mice fed a
HFD. Histological analysis of WAT and quantitation of adi-
pocyte size in the mice revealed signiﬁcantly smaller adipocytes
in adiponectin knockout mice than in wild-type mice. Addi-
tionally, after 2 weeks of HFD, when the two groups were
indistinguishable by body weight, we examined AMPK and
ACC phosphorylation status, AdipoR1 and AdipoR2 expres-
sion, food intake, and oxygen consumption in the two groups.
AMPK and ACC phosphorylation in the ARH was signiﬁ-
cantly suppressed in adiponectin knockout mice after fasting,
although the expression levels of AdipoR1 and AdipoR2 in
the ARH were not signiﬁcantly diﬀerent between the two geno-
types. Daily food intake was signiﬁcantly lower in adiponectin
knockout mice than in wild-type mice, and oxygen consump-
tion was signiﬁcantly greater.Food intake
Energy
expenditure
Food intake
Energy
expenditure
Adipose tissue
Fig. 3. Body fat content is maintained by factors secreted from
adipose tissue, as a result of feedback signals arising from the fat
depots that are sensed by the brain.9. Physiological and pathophysiological roles of adiponectin
These ﬁndings have brought new insights on adiponectin as
an appetite stimulator, longer-term fat modulator, and a star-
vation signal. We propose a hypothesis that adiponectin regu-
lates food intake in coordination with leptin. Under fasting
conditions, the adiponectin signal in the ARH increases; con-
sequently, hypothalamic AMPK is activated, which stimulatesAMPK
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Fig. 4. Under a high-fat diet, adiponectin-induced AMPK in the brain rema
thus further worsening obesity, metabolic syndrome and type 2 diabetes.food intake. After food consumption, on the other hand, the
leptin signal in the ARH increases; consequently, hypotha-
lamic AMPK activity decreases, resulting in reduced food in-
take. Thus, the leptin signal is regulated inversely in relation
to adiponectin signal in the hypothalamus. Adiponectin en-
hances hypothalamic AMPK activity and food intake, as op-
posed to the action of leptin.
In addition to the regulation of food intake, adiponectin and
leptin may also participate in the maintenance of energy
homeostasis. Several gut-derived hormones, such as ghrelin
and insulin, have been discovered as the modulator of energy
balance, which primarily act on appetite. Adipokines appear
to be also involved in this; they mainly regulate body fat mass
as the long-term modulator of energy balance. On facing the
loss of adiposity, the adiponectin signal increases and leptin
signal decreases in the ARH; consequently, hypothalamic
AMPK is activated, which suppresses energy expenditure, pro-
moting fat storage. On facing the excessive adiposity, on the
other hand, the adiponectin signal decreases and the leptin sig-
nal increases in the ARH; consequently, hypothalamic AMPK
activity decreases that stimulates energy expenditure, inhibit-
ing fat accumulation. Thus the fundamental roles of leptin
and adiponectin seem to be to preserve an adequate fat reserve:
leptin acts as a satiety signal, and adiponectin acts as a starva-
tion signal. These observations support the lipostat theory,
and adiponectin is the ﬁrst-identiﬁed adipokine that contrib-
utes to fat accumulation in response to depletion of adiposity
(Fig. 3).Obesity
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develop. Under an excessive fat reserve, serum adiponectin lev-
els are decreased. The HMW form of adiponectin is known to
be most active [13] and does not enter the CSF [23,22]. Under
an obese condition, serum adiponectin levels, especially of ac-
tive HMW multimers, are reported to decrease in an obese
individual and murine models, which decreases muscle and he-
patic AMPK activity and fatty acid combustion, exacerbating
insulin resistance. In the CNS, on the other hand, although a
HMW form of adiponectin in serum decreases under an obese
condition, trimers and hexamers are present, maintaining the
serum adiponectin levels relatively stable in the CSF. Thus,
hypothalamic AMPK activity is not suppressed, not decreas-
ing food intake and energy expenditure. This results in worsen-
ing obesity, metabolic syndrome and type 2 diabetes (Fig. 4).
Lastly, let us consider the role of adiponectin in the history.
During the course of evolution, starvation signals were essen-
tial for the survival of an organism. Adiponectin levels were
likely to be high under the scarce fat reserve of starvation. Tri-
meric and hexameric forms of adiponectin would increase
appetite by aﬀecting the brain to decrease energy expenditure
and to promote fat accumulation. The HMW form of adipo-
nectin was likely to derive energy for survival from combusting
(adipocyte-secreted) FFA in the liver and skeletal muscle. The
increase in peripheral fatty acid combustion may have contrib-
uted to the preferential supply of glucose to the brain. Adipo-
nectin may have played an important role as an starvation
gene (Fig. 5). This may explain why adiponectin receptors ex-
isted earlier than leptin receptors and have been conserved
from yeast to humans [14].
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